{
    "clinical_study": {
        "@rank": "149624", 
        "arm_group": {
            "arm_group_label": "PR5I/Pediacel/PR5I", 
            "arm_group_type": "Experimental", 
            "description": "PR5I/Pediacel/PR5I mixed schedule with concomitant Prevenar 13 / NeisVac-C / RotaTeq"
        }, 
        "brief_summary": {
            "textblock": "To evaluate the immune response and the safety of a primary series schedule that includes\n      V419 (PR5I) at 2 and 6 months of age and Pediacel at 4 months of age\n\n      Primary objectives\n\n        -  To demonstrate that the mixed schedule induces acceptable responses for Hepatitis B one\n           month after completion of the mixed schedule\n\n        -  To demonstrate that the mixed schedule induces acceptable responses for Hib  one month\n           after completion of the mixed schedule\n\n      Secondary objectives\n\n        -  To describe the antibody response to all PR5I antigens one month after completion of\n           the mixed schedule\n\n        -  To describe the antibody response to meningococcal serogroup C (MenC) conjugate vaccine\n           one month after the second dose of MenC vaccine\n\n        -  To describe the safety profile after each dose of study vaccines administered"
        }, 
        "brief_title": "Spanish Mixed HEXA/PENTA/HEXA Schedule", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Neisseria Meningitidis", 
            "Bacterial Infections", 
            "Virus Diseases"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Bacterial Infections", 
                "Virus Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy infant 46 to 74 days (both inclusive)\n\n          -  Documented receipt of only one dose of monovalent hepatitis B vaccine within the 3\n             days after birth\n\n          -  Parent(s)/legal representative able to comply with the study procedures\n\n        Exclusion Criteria:\n\n          -  Participation in any study with an investigational compound or device since birth\n\n          -  History of congenital or acquired immunodeficiency\n\n          -  Chronic illness that could interfere with study conduct or completion\n\n          -  Hypersensitivity to any of the study vaccines components or history of a\n             life-threatening reaction to a vaccine containing the same substances as the study\n             vaccines\n\n          -  Contraindication to Pediacel, NeisVac-C, Prevenar 13, and RotaTeq\n\n          -  History or maternal history of HBsAg seropositivity\n\n          -  Coagulation disorder that contraindicate intramuscular injection\n\n          -  History of vaccination with a Haemophilus influenzae type b conjugate, diphtheria,\n             tetanus, pertussis (acelullar or whole-cell), poliovirus, meningococcal serogroup C\n             conjugate, pneumococcal conjugate containing vaccine(s)\n\n          -  History of hepatitis B, Haemophilus influenzae type b, diphtheria, tetanus,\n             pertussis, poliomyelitis, or serogroup C meningococcal infection\n\n          -  Receipt of immune globulin, blood or blood-derived products since birth\n\n          -  Receipt of systemic corticosteroids for more than 14 consecutive days within one\n             month of the study start\n\n          -  Identified as a natural or adopted child of the Investigator or employee with direct\n             involvement in the proposed study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "76 Days", 
            "minimum_age": "46 Days"
        }, 
        "enrollment": {
            "#text": "385", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01839188", 
            "org_study_id": "PRI02C", 
            "secondary_id": "2012-004221-25"
        }, 
        "intervention": [
            {
                "arm_group_label": "PR5I/Pediacel/PR5I", 
                "description": "Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b conjugate [Meningococcal Outer Membrane Protein Complex], and hepatitis B [Recombinant] Vaccine 0.5 mL intramuscular injection at 2 and 6 months of age", 
                "intervention_name": "PR5I (V419)", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "PR5I/Pediacel/PR5I", 
                "description": "Adsorbed diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliomyelitis and Haemophilus influenzae type b conjugate vaccine 0.5 mL intramuscular injection at 4 months of age", 
                "intervention_name": "Pediacel", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "PR5I/Pediacel/PR5I", 
                "description": "Meningococcal group C polysaccharide conjugate vaccine adsorbed 0.5 mL intramuscular injection at 2 and 4 months of age", 
                "intervention_name": "NeisVac-C", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "PR5I/Pediacel/PR5I", 
                "description": "Human-bovine rotavirus reassortants (live) vaccine 2mL oral administration at 2, 4 and 6 month", 
                "intervention_name": "RotaTeq", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "PR5I/Pediacel/PR5I", 
                "description": "Pneumococcal conjugate vaccine (13-valent, adsorbed) 0.5 mL intramuscular injection at 2 and 4 months of age", 
                "intervention_name": "Prevenar 13", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 16, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "A Coru\u00f1a", 
                        "country": "Spain"
                    }, 
                    "name": "Sanofi Pasteur MSD Investigational Site 004"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Almeria", 
                        "country": "Spain"
                    }, 
                    "name": "Sanofi Pasteur MSD Investigational Site 015"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Almeria", 
                        "country": "Spain"
                    }, 
                    "name": "Sanofi Pasteur MSD Investigational Site 016"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Burriana", 
                        "country": "Spain"
                    }, 
                    "name": "Sanofi Pasteur MSD Investigational Site 012"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cuart de Poblet", 
                        "country": "Spain"
                    }, 
                    "name": "Sanofi Pasteur MSD Investigational Site 010"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "La Eliana", 
                        "country": "Spain"
                    }, 
                    "name": "Sanofi Pasteur MSD Investigational Site 008"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paiporta", 
                        "country": "Spain"
                    }, 
                    "name": "Sanofi Pasteur MSD Investigational Site 011"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pontevedra", 
                        "country": "Spain"
                    }, 
                    "name": "Sanofi Pasteur MSD Investigational Site 003"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Santiago de Compostela", 
                        "country": "Spain"
                    }, 
                    "name": "Sanofi Pasteur MSD Investigational Site 001"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sevilla", 
                        "country": "Spain"
                    }, 
                    "name": "Sanofi Pasteur MSD Investigational Site 014"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Valencia", 
                        "country": "Spain"
                    }, 
                    "name": "Sanofi Pasteur MSD Investigational Site 006"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Valencia", 
                        "country": "Spain"
                    }, 
                    "name": "Sanofi Pasteur MSD Investigational Site 013"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Valencia", 
                        "country": "Spain"
                    }, 
                    "name": "Sanofi Pasteur MSD Investigational Site 007"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Valencia", 
                        "country": "Spain"
                    }, 
                    "name": "Sanofi Pasteur MSD Investigational Site 009"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vilagarcia de Arousa", 
                        "country": "Spain"
                    }, 
                    "name": "Sanofi Pasteur MSD Investigational Site 005"
                }
            }
        ], 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 3 Open-label Study to Evaluate the Immunogenicity and Safety of a Mixed (HEXA/PENTA/HEXA) Primary Series Schedule That Includes V419 (PR5I) at 2 and 6 Months of Age and Pediacel at 4 Months of Age.", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Proportion of subjects with an anti-hepatitis B titre \u226510 mIU/mL", 
                "safety_issue": "No", 
                "time_frame": "Month 7 (one month after the complete mixed schedule PR5I/Pediacel/PR5I)"
            }, 
            {
                "measure": "Proportion of subjects with an anti-polyribosylribitol phosphate (PRP) titre \u22650.15 \u00b5g/mL", 
                "safety_issue": "No", 
                "time_frame": "Month 7 (one month after the complete mixed schedule PR5I/Pediacel/PR5I)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01839188"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Proportion of subjects with an anti-diphtheria concentration \u22650.01 IU/mL", 
                "safety_issue": "No", 
                "time_frame": "Month 7 (one month after the complete mixed schedule PR5I/Pediacel/PR5I)"
            }, 
            {
                "measure": "Proportion of subjects with an anti-tetanus concentration \u22650.01 IU/mL", 
                "safety_issue": "No", 
                "time_frame": "Month 7 (one month after the complete mixed schedule PR5I/Pediacel/PR5I)"
            }, 
            {
                "measure": "Proportion of subjects with an anti-inactivated poliovirus 1 titre \u22651:8 dil", 
                "safety_issue": "No", 
                "time_frame": "Month 7 (one month after the complete mixed schedule PR5I/Pediacel/PR5I)"
            }, 
            {
                "measure": "Proportion of subjects with an anti-inactivated poliovirus 2 titre \u22651:8 dil", 
                "safety_issue": "No", 
                "time_frame": "Month 7 (one month after the complete mixed schedule PR5I/Pediacel/PR5I)"
            }, 
            {
                "measure": "Proportion of subjects with an anti-inactivated poliovirus 3 titre \u22651:8 dil", 
                "safety_issue": "No", 
                "time_frame": "Month 7 (one month after the complete mixed schedule PR5I/Pediacel/PR5I)"
            }, 
            {
                "measure": "Geometric Mean Titers for pertussis", 
                "safety_issue": "No", 
                "time_frame": "Month 7 (one month after the complete mixed schedule PR5I/Pediacel/PR5I)"
            }, 
            {
                "measure": "Proportion of subjects with an anti-MenC titre \u2265 1:8dil", 
                "safety_issue": "No", 
                "time_frame": "Month 5 (one month after the second dose of MenC vaccine)"
            }, 
            {
                "measure": "Solicited injection-site reactions and systemic adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 to Day 5 following vaccination"
            }, 
            {
                "measure": "Unsolicited injection-site and systemic adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 to Day 15 following vaccination"
            }, 
            {
                "measure": "Serious adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "From signature of the informed consent to the last visit of the subject, an expected average of 5 months"
            }
        ], 
        "source": "Sanofi Pasteur MSD", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Sanofi Pasteur, a Sanofi Company", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Merck Sharp & Dohme Corp.", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Sanofi Pasteur MSD", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}